secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0001193125-23-095838
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics adds Dr. Barbara Klencke to board and promotes three to SVP
------------------------------------------------------------------------------

- Dr. Barbara Klencke appointed to board effective April 6, 2023; granted option for 9,146 shares vesting over 36 months.
- Klencke brings 20+ years oncology drug development; was CMO of Sierra Oncology (acquired by GSK in 2022).
- Shrikanta Chattopadhyay promoted to SVP, Medical, Translational Medicine; 15+ years experience.
- Ann Hargraves promoted to SVP, Human Resources; previously led HR at Keurig and founded Mindset Consulting.
- Ray Lockard promoted to SVP, Technical Operations and Quality; over 25 years in manufacturing and supply chain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523095838/0001193125-23-095838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523095838/d494333d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-095838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer